ArticleJournal of tissue engineering and regenerative medicine2019
Successful development and clinical translation of a novel anterior lamellar artificial cornea.
Article in Journal of tissue engineering and regenerative medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Advances in Corneal Tissue Engineering: Comparative Performance of Bioengineered Grafts in Animal Models.Medicina (Kaunas, Lithuania) · 2025Pooled it
- Bioartificial human corneas generated by tissue engineering. A historical and technical review.Histology and histopathology · 2026Review
- Generation of a Bioengineered Substitute of the Human Sclero-Corneal Limbus Using a Novel Decellularization Method.Pharmaceutics · 2025Article
- FXa-Responsive Hydrogels to Craft Corneal Endothelial Lamellae.Advanced healthcare materials · 2025Article
- Understanding the cellular dynamics, engineering perspectives and translation prospects in bioprinting epithelial tissues.Bioactive materials · 2025Review
- Histological and Histochemical Methods for the Evaluation of Tissue Engineered Skin Substitutes.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Article
- Histological, histochemical, and immunohistochemical characterization of NANOULCOR nanostructured fibrin-agarose human cornea substitutes generated by tissue engineering.BMC medicine · 2024Article
- Article
- Fibrin and Marine-Derived Agaroses for the Generation of Human Bioartificial Tissues: An Ex Vivo and In Vivo Study.Marine drugs · 2023Article
- The origin of human epithelial tissue.Histology and histopathology · 2023Review
- Derivation of Limbal Stem Cells from Human Adult Mesenchymal Stem Cells for the Treatment of Limbal Stem Cell Deficiency.International journal of molecular sciences · 2023Article
- Identification of histological threshold concepts in health sciences curricula: Students' perception.Anatomical sciences education · 2023Article
- Development of stromal differentiation patterns in heterotypical models of artificial corneas generated by tissue engineering.Frontiers in bioengineering and biotechnology · 2023Article
- Optical Behavior of Human Skin Substitutes: Absorbance in the 200-400 nm UV Range.Biomedicines · 2022Article
- Artificial cornea transplantation and visual rehabilitation: an integrative review.Arquivos brasileiros de oftalmologia · 2022Review
- Inactivation of human plasma alters the structure and biomechanical properties of engineered tissues.Frontiers in bioengineering and biotechnology · 2022Article
- Information and Scientific Impact of Advanced Therapies in the Age of Mass Media: Altmetrics-Based Analysis of Tissue Engineering.Journal of medical Internet research · 2021Article
- Usefulness of a Nanostructured Fibrin-Agarose Bone Substitute in a Model of Severely Critical Mandible Bone Defect.Polymers · 2021Article
- Tissue Engineering Meets Nanotechnology: Molecular Mechanism Modulations in Cornea Regeneration.Micromachines · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Blindness due to corneal diseases is a common pathology affecting up to 23 million individuals worldwide. The tissue-engineered anterior human cornea, which is currently being tested in a Phase I/II clinical trial to treat severe corneal trophic ulcers with preliminary good feasibility and safety results. This bioartificial cornea is based on a nanostructured fibrin-agarose biomaterial containing human allogeneic stromal keratocytes and cornea epithelial cells, mimicking the human native anterior cornea in terms of optical, mechanical, and biological behavior. This product is manufactured as a clinical-grade tissue engineering product, fulfilling European requirements and regulations. The clinical translation process included several phases: an initial in vitro and in vivo preclinical research plan, including preclinical advice from the Spanish Medicines Agency followed by additional preclinical development, the adaptation of the biofabrication protocols to a good manufacturing practice manufacturing process, including all quality controls required, and the design of an advanced therapy clinical trial. The experimental development and successful translation of advanced therapy medicinal products for clinical application has to overcome many obstacles, especially when undertaken by academia or SMEs. We expect that our experience and research strategy may help future researchers to efficiently transfer their preclinical results into the clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.